What to expect from genomic tumour profiling for cancer of unknown primary

Cancer of unknown primary means cancer has been found, but tests have not identified where it began. Profiling studies genetic changes in the cancer cells. Some findings may point toward a medicine aimed at a particular molecular feature, while others may support a broader treatment approach.

The profile does not always identify the original organ, and it cannot replace scans, pathology review, or examination. The team interprets it with the cancer’s appearance under the microscope, sites involved, symptoms, previous tests, and your general health.

The laboratory may use tissue already removed during a biopsy. Ask whether there is enough suitable material, whether a new biopsy is being considered, and what discomfort or preparation that procedure involves. Tell the team about medicines, allergies, and any treatment already received.

When the report returns, ask which findings are clinically useful now and which are uncertain. Discuss whether a matched treatment, a standard treatment, or another diagnostic step is being considered. A result with no clear match is still information and does not mean care has stopped.

Seek urgent medical help for severe breathing difficulty, new confusion, sudden weakness, uncontrolled bleeding, or rapidly worsening pain. Do not wait for a profiling report when symptoms change quickly; the clinical team can assess and treat immediate problems separately.

Ask: Could profiling help identify a treatment target? Is my existing biopsy adequate? Could another biopsy change the information available? Which findings are confirmed and which are uncertain? What treatment choices remain if no useful alteration is found? When will we discuss the report?